

Opioid Use Disorder (OUD)-Pharmacist's Role

David Butterfield, PharmD, BCPS, BCPP

Clinical Pharmacy Specialist, Outpatient Psychiatry, Eskenazi Health





Learning Objectives

- Understand the different roles of a pharmacist
- Evaluate ways pharmacists can positively impact the treatment of Opioid Use Disorder
- Understand the impact of Clinical Pharmacy Services in patient care





Different Roles of A Pharmacist

- Retail Setting (CVS, Walgreens, Independent Chains, etc.)
- Hospital Setting (Central Distribution, Clinical)
- Outpatient Clinical (CVRR, Psychiatry, Oncology, HIV/ID, etc.)
- Academia
- Research/Industry



Image accessed: https://www.commonwealthfund.org/publications/issue-briefs/2019/mar/pharmacy-benefit-managers-practices-controversies-what-lies-ahead



Pharmacist's Role in OUD

Collaborate with prescriber

Assess for misuse potential

Naloxone access

Medication counseling

Utilize SBIRT- Screening, Brief Intervention, Referral to Treatment

Clinical pharmacy services



Collaborate with Prescriber


- Perform pill counts
- Review prescription drug monitoring program
- Enforce policy of no early refills
- Hold patient accountable to treatment agreement
- Stay in direct communication
 - Voice Concerns
 - Drug Interactions





Misuse Potential- Red Flags

- Use of many pharmacies and doctors
- Obtain prescription from provider outside of their scope of practice
- Prescriptions with high dosages/quantities
- Pays in cash/will not use insurance coverage
- Demands certain brands of medication
- Requests early refills frequently
- Fills only controlled substance despite having other prescriptions





- Considered for all patients exposed to opioids
 - Pain, misuse, risk of accidental exposure, family members
- Overdose risk factors:
 - Benzos and alcohol, opioid addiction/SUD, comorbid mental illness, recent incarceration, etc.
- Naloxone for home use can be intramuscular or intranasal






Naloxone Formulations

Туре	Contents	Instructions	Image
Intranasal	2 mg/0.1 mL 4mg/0.1 mL 8mg/0.1 mL	One spray into nostril upon signs of opioid overdose. Call 911. May repeat x 1.	NARCAN datase 10 NASAL SPRAY (1898) NASAL SPRAY (1898) NOT SPRAY
Intramuscular	0.4 mg/mL vial 1 mg/mL vial 5mg/0.5 mL vial	Inject IM upon signs of opioid overdose. Call 911. May repeat x 1.	The state of the s



- Store in an easily accessible place in the original package at room temperature
- Avoid light exposure
- The shelf life is typically 12 to 18 months
 - If stored correctly naloxone should be effective up until BUD date on packaging
- Do not insert naloxone into prefilled syringe until ready to use
 - Once inserted it expires within 2 weeks
- Monitor expiration and replace when expired
 - If no other alternatives exist at the time, administer expired naloxone





Supporting Laws and Regulations

Law/Regulation	Explanation
Good Samaritan	Protects individuals who call for help at the scene of an overdose from being arrested for drug possession
Liability protection/third party administration	Protects the prescriber, pharmacist, and the bystander who may be administering naloxone. It also allows bystander to be prescribed naloxone for use on opioid overdose victims.
Collaborative Practice Agreement/Standing Order	Allows pharmacists to dispense naloxone to atrisk individuals without a traditional prescription. Recent study found that states with this law saw significant decrease in opioid related mortality.





Buprenorphine Considerations

- Ensure appropriate quantity available
- Assist with issues that could delay dispensing
 - Conversions, dosage formulations, manufacturer coupons, vouchers, and savings program
- Induction process requires frequent refills
 - Adherence checks
 - Wellness checks
 - Supervised dosing





Counseling Points for Buprenorphine

- Sublingual tablet should be kept under tongue until completely dissolved
 - Buprenorphine is not well absorbed orally
 - Swallowing will result in reduction of dose/effect
- Buprenorphine/naloxone should not be initiated until patient is in mild withdrawal
- Risk of respiratory depression when used in combination (benzos, alcohol, etc.)



Counseling Points for Naltrexone

- Wait at least 7 to 10 days after discontinuing opioids to prevent inducing opioid withdrawal
 - May need to wait 14 days with transition from methadone/buprenorphine
- Risk of overdose is increased during waiting period to initiate naltrexone as patient's opioid tolerance may be reduced
- Risk of overdose if using opioids while taking naltrexone
- Wallet card for patient's on naltrexone





Wallet Card- Long-Acting Naltrexone







- Screening, Brief Intervention, Referral to Treatment
- Pharmacist- highly accessible healthcare provider
 - Patient encounters 1.5-10 times more than PCP
 - Opportunity for intervention
- Resource list
 - Identification of buprenorphine prescribers
 - Local substance use treatment referral programs
 - Screening tools
 - PCP, self-help groups, employee assistance programs



Image Accessed: https://www.samhsa.gov/sbirt



SBIRT- Helpful Resources

- 1. SAMHSA behaviors health treatment services locator (which includes substance use disorder treatment): National Helpline 1-800-662-HELP (4357), https://findtreatment.samhsa.gov/
- 2. SAMHSA buprenorphine treatment physician locator: http://www.samhsa.gov/medication-assisted-treatment/physician-program-data/treatment-physician-locator/
- 3. SAMHSA opioid treatment program directory: http://dpt2.samhsa.gov/treatment/directory.aspx
- 4. National Institute on Drug Abuse http://www.nida.nih.gov
- 5. Risk assessment tools http://www.opioidrisk.com/node/774
- 6. VIGIL helps pharmacists screen controlled substances https://www.pharmacist.com/vigil-helps-pharmacists-screen-controlled-substances
- 7. A pharmacist's corresponding responsibilities and red flags of diversion http://deachronicles.quarles.com/2013/08/a-pharmacists-obligation-corresponding-responsibility-and-red-flags-of-diversion/; http://www.deadiversion.usdoj.gov/pubs/brochures/pharmguide.htm
- 8. ER/LA opioid analgesics REMS: The extended-release and long-acting opioid analgesics risk evaluation and mitigation strategy http://www.er-la-opioidrems.com/lwgUI/rems/home.action



Clinical Pharmacy Services

 Pilot Study- provide clinical pharmacy services in Adult Addictions Clinic at Eskenazi Health

- Medication reconciliation
- Patient and family education
- New medication education to staff
- Secure funding for medications
- Drug information questions
- Adherence Counseling
- Collaborative practice agreement
 - Up-titration of medications
 - Co-morbid psychiatric medications





Evidence Supporting Clinical Pharmacist

- Study evaluated a pharmacist working 1 day per week in clinic treating individuals with OUD
 - Estimated annualized cost savings of 110,000 dollars
 - Program demonstrated 91% attendance rate, 100% 6 month retention rate, 73% 12 month retention rate
 - 98% of urine screens positive for buprenorphine and 88% were positive for buprenorphine and negative for opioids





Evidence Supporting Clinical Pharmacist


- 2021 feasibility study transitioned maintenance appointments for 71 patients maintained on buprenorphine treatment for OUD from physician to clinical pharmacist
 - 88.7% of patents were retained in treatment
 - 95.3% buprenorphine adherence rates
 - 4.9% of UDS were opioid-positive
- Satisfaction survey
 - 98.4% rated their satisfaction as satisfied (7.9%) or very satisfied (90.5%) with the quality of treatment offered by the study
 - 96.8% reported that treatment transfer to pharmacist care was not difficult at all
 - 100% of the pharmacists and physicians involved in the study reported being very satisfied with their overall experience in this study
 - 100% of the pharmacists and physicians involved in the study were either very satisfied (91.7%) or satisfied (8.3%) with the quality of treatment offered in this study





Evidence Supporting Clinical Pharmacist

- Pilot study to establish collaborative practice agreement in a primary care setting for patients with OUD
 - Clinical pharmacist was responsible for initial evaluations, buprenorphine inductions, and follow-up visits
 - Pharmacist titrated buprenorphine doses collaboratively with a supervising psychiatrist based on opioid cravings, illicit opioid use, UDS, and pain scores
 - Clinical endpoints indicate treatment retention and aberrant urine toxicology did not differ between clinical pharmacist and psychiatrist





Business Plan

- Clinical Measures- validated tool that assigns dollar value to pharmacist interventions
 - 62 patient interventions made in 10 days- annualized cost savings ~\$200,000
 - Inhaler causing thrush
 - Long acting inhaler prn instead maintenance
 - Patient drinking orange juice when blood sugars high- 2 DKA admissions in one year
 - Metabolic lab monitoring
- Minimize number of medication fees waived
 - Annualized ~\$14,000
- Decrease medication errors
 - 1 error caught in 10 clinic days
 - Average med error-~\$2,000 with annualized savings ~\$57,000
- Billing revenue
 - Estimated around 300,000 dollars of annual revenue generation



Work as a physician extender

Assess/encourage patient adherence

Counsel on medications

Expand naloxone access

Screen, Intervene, and Refer to Treatment

Clinical Pharmacy Services in Adult Addiction Clinics